Интерфейс «мозг-компьютер» с моторными образами в реабилитации двигательной дисфункции верхних конечностей после инсульта

Executive Industry Relevance

Motor imagery brain-computer interface (MI-BCI) offers a non-invasive, mechanism-driven approach to address upper limb motor dysfunction in post-stroke rehabilitation, targeting a critical bottleneck in neurorestorative R&D. By integrating real-time neurophysiological monitoring and adaptive task protocols, MI-BCI enhances predictive confidence in functional recovery and supports translational continuity from mechanistic insight to clinical application. This capability is strategically positioned to inform portfolio decisions and de-risk early-stage neurorehabilitation assets.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Enables interrogation of central-peripheral code loop mechanisms underlying motor recovery.
• Supports functional target validation through quantitative neuroimaging and behavioral endpoints.
• Facilitates mechanistic de-risking by linking cortical activation patterns to clinical function.

Screening & Assay Development

• Establishes standardized, reproducible MI-BCI protocols for evaluating neurorehabilitation interventions.
• Generates quantitative outputs via Fugl-Meyer and Wolf Motor Function Tests for objective assessment.
• Prepares validated patient cohorts and data streams for downstream screening of adjunctive therapies.

Translational & Preclinical Research

• Aligns functional near-infrared spectroscopy (fNIRS) biomarkers with disease-relevant motor and cognitive endpoints.
• Enables continuity from discovery-stage mechanistic studies to preclinical and early clinical validation.
• Supports risk-adjusted advancement by integrating neurophysiological and behavioral data.

Pipeline & Workflow Integration

MI-BCI protocols bridge early discovery, target validation, and translational research by providing standardized, quantitative, and mechanistically anchored assessments of neurorehabilitation interventions.

• Discovery Biology: Supports hypothesis testing of central-peripheral integration in motor recovery.
• Screening: Delivers reproducible, quantitative motor and cognitive function readouts for intervention assessment.
• Analytics: Provides real-time fNIRS and EEG data for comparative analysis across patient cohorts.
• Translational Research: Aligns functional and neuroimaging biomarkers for preclinical-to-clinical continuity.
• Enterprise Reuse: Offers a scalable, adaptable platform for ongoing neurorehabilitation R&D initiatives.

Operational & Enterprise Impact

• Scientific Value: Increases predictive confidence in neurorehabilitation outcomes and reduces mechanistic ambiguity.
• Operational Value: Standardizes patient assessment and intervention protocols for reproducibility and scalability.
• Strategic Value: Informs go/no-go decisions and optimizes resource allocation in neurorestorative portfolios.
• Portfolio Impact: Enables risk-adjusted prioritization of neurorehabilitation assets based on quantitative endpoints.

Implementation Considerations

• Requires expertise in neurophysiology, EEG/fNIRS instrumentation, and clinical assessment protocols.
• Demands robust analytical infrastructure for real-time data acquisition and processing.
• Necessitates cross-team standardization of training, assessment, and data management workflows.
• Adaptation across diverse patient populations and stroke severities may require protocol customization.
• Signal quality and patient compliance are practical limitations that must be managed during implementation.

Biopharma FAQs